Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of cannabidiol in preparation of medicine for treating acute B lymphocytic leukemia

A technology of B lymphocytes and cannabidiol, which is applied in the field of biomedicine and can solve the problems that cannot be used to predict efficacy and the like

Inactive Publication Date: 2021-03-30
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this article is limited to the results of cannabidiol (CBD) on T-ALL and cannot be used to predict the efficacy on B-ALL

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cannabidiol in preparation of medicine for treating acute B lymphocytic leukemia
  • Application of cannabidiol in preparation of medicine for treating acute B lymphocytic leukemia
  • Application of cannabidiol in preparation of medicine for treating acute B lymphocytic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033]Embodiment 1, the inhibitory effect of cannabidiol (CBD) on the survival of human acute lymphoblastic leukemia cell Nalm-6 in vitro

[0034] Cannabidiol (CBD) was dissolved in DMSO to a concentration of 50 μM and stored at -20°C until use. Cannabidiol (CBD) was further diluted to the required concentration before use, and the DMSO concentration was determined to be less than 0.001%. The human acute B-lymphoblastic leukemia cell Nalm-6 used in this experiment was used as the test cell. The cells were cultured at 37°C in a humid atmosphere with 5% CO2 and 95% air, and the culture medium was RPMI-1640 containing 10% heat-inactivated fetal bovine serum. The survival rate of human acute B-lymphoblastic leukemia cells Nalm-6 at different concentrations of cannabidiol (CBD) was tested.

[0035] result: figure 1 Describes the survival of Nalm-6 human acute lymphoblastic leukemia cells when cannabidiol (CBD) is administered. It can be seen that as the dose of cannabidiol (CBD...

Embodiment 2

[0036] Embodiment 2, cannabidiol (CBD) is to the inhibitory effect of human acute lymphoblastic leukemia cell Reh survival in vitro

[0037] Cannabidiol (CBD) was dissolved in DMSO to a concentration of 50 μM and stored at -20°C until use. Cannabidiol (CBD) was further diluted to the required concentration before use, and the DMSO concentration was determined to be less than 0.001%. The human acute B-lymphoblastic leukemia cell line Reh used in this experiment was used as the test cell. The cells were cultured at 37°C in a humid atmosphere with 5% CO2 and 95% air, and the culture medium was RPMI-1640 containing 10% heat-inactivated fetal bovine serum. The survival of human acute B-lymphoblastic leukemia cells Reh was tested at various concentrations of cannabidiol (CBD).

[0038] result: figure 2 The survival of human acute B-lymphoblastic leukemia cells Reh in response to cannabidiol (CBD) administration is described. It can be seen that as the dose of cannabidiol (CBD) ...

Embodiment 3

[0039] Embodiment 3, cannabidiol (CBD) is to human acute lymphoblastic leukemia cell RS4 in vitro; 11 survival inhibitory effect

[0040] Cannabidiol (CBD) was dissolved in DMSO to a concentration of 50 μM and stored at -20°C until use. Cannabidiol (CBD) was further diluted to the required concentration before use, and the DMSO concentration was determined to be less than 0.001%. The human acute lymphoblastic leukemia cell line RS4;11 used in this experiment was used as the test cell. The cells were cultured at 37°C in a humid atmosphere with 5% CO2 and 95% air, and the culture medium was RPMI-1640 containing 10% heat-inactivated fetal bovine serum. The survival of human acute B-lymphoblastic leukemia cells RS4;11 was tested at various cannabidiol (CBD) concentrations.

[0041] result: image 3 The viability of human acute B-lymphoblastic leukemia cells RS4;11 in response to cannabidiol (CBD) administration is described. It can be seen that as the dose of cannabidiol (CBD)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of cannabidiol in preparation of a medicine for treating acute B lymphocytic leukemia. The invention provides a new medical application of cannabidiol (CBD), which can effectively reduce the survival rate of acute B lymphocytic leukemia cells, does not influence the survival of normal cells under the effective dosage of leukemia cells, and provides a potential medicine for treating acute B lymphocytic leukemia.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of cannabidiol (CBD) in the preparation of products for treating acute B lymphocytic leukemia. Background technique [0002] Acute lymphoblastic leukemia (ALL) is a relatively common type of leukemia, mainly due to the differentiation disorder, uncontrolled proliferation and blocked apoptosis of lymphoid hematopoietic progenitor cells, a large number of abnormal clones of tumor cells inhibit the normal hematopoietic system , leading to serious clinical symptoms and complications. ALL is more common in children, and it is one of the most common malignant tumors and the main cause of death in childhood. In my country, the incidence of childhood leukemia is 4-6 / 100,000, and the incidence is increasing year by year, accounting for more than 75% of childhood leukemia. . With the application of combined chemotherapy and supportive therapy, the disease-free surviv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/05A61P35/02
CPCA61K31/05A61P35/02
Inventor 冯敏张寒
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com